首页> 外文OA文献 >S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

【2h】

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

机译：S-1和Oxaliplatin（Sox）加贝伐单抗与Mfolfox6加上贝伐单抗作为转移性结肠直肠癌患者的一线治疗：更新了开放标签，非劣势，随机阶段III：软化研究的整体存活分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Hideo Baba; Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Kazuhiro Yoshida; Masato Nakamura; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial [J] . YamadaY., TakahariD., MatsumotoH., The lancet oncology . 2013,第13期

机译：白细胞素，氟尿嘧啶和奥沙利铂联合贝伐单抗与S-1和奥沙利铂联合贝伐单抗在转移性结直肠癌（SOFT）患者中的应用：一项开放性，非劣效，随机，3期临床研究
2. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial [J] . Yamada Y., Denda T., Gamoh M., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：S-1和Irinotecan Plus Bevacizumab与Mfolfox6或Capeox Plus Bevacizumab作为转移性结肠直肠癌患者的一线治疗（三洛丽岭）：随机，开放标签，III，非流动性试验
3. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial [J] . Yamada Y., Denda T., Gamoh M., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第3期

机译：S-1和Irinotecan Plus Bevacizumab与Mfolfox6或Capeox Plus Bevacizumab作为转移性结肠直肠癌患者的一线治疗（三洛丽岭）：随机，开放标签，III，非流动性试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label non-inferiority randomised phase III: SOFT study [O] . Hideo Baba, Yasuhide Yamada, Daisuke Takahari, 2017

机译：S-1和奥沙利铂（SOX）加贝伐单抗与mFOLFOX6加贝伐单抗作为转移性结直肠癌患者的一线治疗：开放标签非自卑性随机III期的最新总体生存分析：SOFT研究
6. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial [O] . Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, 2020

机译：Upfront folfoxiri加贝伐单抗和次曲后的重新引入与mfolfox6 plus bevacizumab，然后是Folfiri加Bevacizumab治疗转移性结肠直肠癌（Tribe2）：多期，开放标签，第3阶段，随机，受控试验

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

著录项

引文网络

相似文献

相关主题

期刊订阅